Parameter
| Biomarker | TMB (Tumor mutation burden) | Full name | Tumor Mutation Burden | Molecular Type | Genomic signatures (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction, Prognosis | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Tumor tissue (NGS), circulating tumor DNA (ctDNA, NGS) | ||
| Pathobiological Mechanisms | It refers to the number of somatic mutations per million bases in the tumor genome. Gastric cancer with high TMB (TMB-H) produces more neoantigen due to mutation accumulation, which can activate stronger anti-tumor immune response | ||||
| Clinical Availability Status | Clinical research stage: most of them are in phase II/III clinical verification, and some centers have used it as a reference index for immunotherapy | ||||
| Notes and Dynamics | Tmb-h and MSI-H/dMMR partially overlap in gastric cancer, but there is also an independent TMB-H population. Dynamic monitoring of TMB by ctDNA can reflect the evolution of tumor mutation in real time and guide the adjustment of immunotherapy. Standardized detection Panel is the future direction | ||||